Cinnarizine
- Generic Name
- Cinnarizine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28N2
- CAS Number
- 298-57-7
- Unique Ingredient Identifier
- 3DI2E1X18L
- Background
First synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear an...
- Indication
For the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.
- Associated Conditions
- Balance Disorders, Dizziness, Motion Sickness, Nausea, Peripheral Arterial Disease (PAD), Raynaud's Phenomenon, Vertigo, Inadequate cerebral circulation, Peripheral vasculopathy
- Associated Therapies
- -
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 15
- Registration Number
- NCT05686993
- Locations
- 🇬🇧
St Bartholomew's Hospital, London, United Kingdom
A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness
Not Applicable
- Conditions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Medical Corps, Israel Defense Force
- Target Recruit Count
- 100
- Registration Number
- NCT01198106
- Locations
- 🇮🇱
base 30 IAF, Yavne, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath